PD-1 Antibodies
First Claim
Patent Images
1. An antibody that binds human PD-1 (SEQ ID NO:
- 1), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences RASQGISSWLA (SEQ ID NO;
9), SAASSLQS (SEQ ID NO;
10), and QQANHLPFT (SEQ ID NO;
11), respectively, and wherein the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 consists of the amino acid sequences KASGGTFSSYAIS (SEQ ID NO;
2) or KASGGTLSSYAIS (SEQ ID NO;
3), wherein HCDR2 consists of the amino acid sequences LIIPMFGTAGYAQKFQG (SEQ ID NO;
4), LIIPMFDTAGYAQKFQG (SEQ ID NO;
5) or LIIPMFGAAGYAQRFQG (SEQ ID NO;
6), and wherein HCDR3 consists of the amino acid sequences ARAEYSSTGTFDY (SEQ ID NO;
7) or ARAEHSSTGTFDY (SEQ ID NO;
8).
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
-
Citations
31 Claims
-
1. An antibody that binds human PD-1 (SEQ ID NO:
- 1), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences RASQGISSWLA (SEQ ID NO;
9), SAASSLQS (SEQ ID NO;
10), and QQANHLPFT (SEQ ID NO;
11), respectively, and wherein the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 consists of the amino acid sequences KASGGTFSSYAIS (SEQ ID NO;
2) or KASGGTLSSYAIS (SEQ ID NO;
3), wherein HCDR2 consists of the amino acid sequences LIIPMFGTAGYAQKFQG (SEQ ID NO;
4), LIIPMFDTAGYAQKFQG (SEQ ID NO;
5) or LIIPMFGAAGYAQRFQG (SEQ ID NO;
6), and wherein HCDR3 consists of the amino acid sequences ARAEYSSTGTFDY (SEQ ID NO;
7) or ARAEHSSTGTFDY (SEQ ID NO;
8). - View Dependent Claims (2, 3, 4, 28, 29, 30, 31)
- 1), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences RASQGISSWLA (SEQ ID NO;
-
5. An antibody, comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR has the amino acid sequence given in SEQ ID NO:
- 15, and the HCVR has the amino acid sequence given in SEQ ID NO;
12, SEQ ID NO;
13, or SEQ ID NO;
14. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
- 15, and the HCVR has the amino acid sequence given in SEQ ID NO;
-
25. A mammalian cell comprising a DNA molecule comprising a polynucleotide sequence encoding a polypeptide having an amino acid sequence of SEQ ID NO:
- 22 and a polynucleotide sequence encoding a polypeptide having an amino acid sequence of SEQ ID NO;
17 or SEQ ID NO;
20, wherein the cell is capable of expressing an antibody comprising a light chain having an amino acid sequence of SEQ ID NO;
22 and a heavy chain having an amino acid sequence of SEQ ID NO;
17 or SEQ ID NO;
20. - View Dependent Claims (26, 27)
- 22 and a polynucleotide sequence encoding a polypeptide having an amino acid sequence of SEQ ID NO;
Specification